If an IgM antibody is produced to a site on a self- or “cancer antigen” that has been glycosylated in response to tumor formation, then it is unlikely that other classes of antibodies will be made to the exact same site if MHC presentation does not occur. This evidence concerns the gene CD40LG and neoplasm.